Search

Memorial Sloan Kettering DCN1-UBC12 Inhibitor Patent Granted

The USPTO granted US Patent 12605373B2 to Memorial Sloan Kettering Cancer Center on April 21, 2026. The patent covers substituted 1-phenyl-3-(piperidin-4-yl)urea analogs as inhibitors of DCN1-UBC12 interaction and DCN1-mediated cullin-RING ligase activity. The application (18596521) was filed March 5, 2024, with 14 claims allowed.

USPTO Patent Grant: Theranostic Agents for PSMA Positive Cancers

The USPTO has granted a patent (US12582728B2) to Memorial Sloan Kettering Cancer Center for theranostic agents targeting PSMA positive cancers. The patent covers compositions and methods for detecting and treating cancer using novel radiohalogenated PSMA targeting agents for diagnostic imaging and radiation therapy.